

118TH CONGRESS
1ST SESSION

H. R. 6749

To require the Director of the National Institutes of Health to evaluate the results and status of completed and ongoing research related to menopause, perimenopause, or mid-life women's health, to conduct and support additional such research, and for other purposes.

IN THE HOUSE OF REPRESENTATIVES

DECEMBER 13, 2023

Ms. CLARKE of New York (for herself, Mrs. LESKO, Ms. BLUNT ROCHESTER, Ms. HOULAHAN, Mr. RYAN, Ms. WILD, Ms. LEE of California, Mrs. CAMMACK, Ms. VELÁZQUEZ, Mr. POSEY, Ms. SEWELL, Mr. GRIJALVA, Ms. TLAIB, Ms. WILLIAMS of Georgia, Mrs. RAMIREZ, Mr. TONKO, Ms. NORTON, Mr. NADLER, Ms. MOORE of Wisconsin, Mr. DAVIS of North Carolina, Ms. PORTER, Mr. GREEN of Texas, Ms. CROCKETT, Mr. ALLRED, Mrs. CHERFILUS-McCORMICK, Ms. KELLY of Illinois, Mr. JACKSON of Illinois, Mr. LAWLER, Mrs. WATSON COLEMAN, Ms. BARRAGÁN, Ms. CARAVEO, Mr. GARCÍA of Illinois, Mr. TRONE, Mr. VARGAS, Mrs. BEATTY, Mrs. FLETCHER, Mr. FITZPATRICK, Ms. KUSTER, Ms. ADAMS, Ms. PINGREE, and Mr. TAKANO) introduced the following bill; which was referred to the Committee on Energy and Commerce

A BILL

To require the Director of the National Institutes of Health to evaluate the results and status of completed and ongoing research related to menopause, perimenopause, or mid-life women's health, to conduct and support additional such research, and for other purposes.

1 *Be it enacted by the Senate and House of Representa-*
2 *tives of the United States of America in Congress assembled,*

1 **SECTION 1. SHORT TITLE.**

2 This Act may be cited as the “Menopause Research
3 and Equity Act of 2023”.

4 **SEC. 2. EVALUATION OF COMPLETED AND ONGOING RE-**
5 **SEARCH RELATED TO MENOPAUSE,**
6 **PERIMENOPAUSE, OR MID-LIFE WOMEN’S**
7 **HEALTH.**

8 (a) IN GENERAL.—The Director of the National In-
9 stitutes of Health shall—

10 (1) conduct an evaluation of—

11 (A) the results of research related to meno-
12 pause, perimenopause, or mid-life women’s
13 health that is complete;

14 (B) the status of such research that is on-
15 going; and

16 (C) any gaps in knowledge and research
17 on—

18 (i) treatments for menopause-related
19 symptoms; and

20 (ii) the safety and effectiveness of
21 treatments for menopause-related symp-
22 toms; and

23 (2) as part of such evaluation, identify the total
24 amount of funding allocated by the National Insti-
25 tutes of Health for the conduct or support of re-
26 search related to menopause, perimenopause, or

1 mid-life women’s health over the preceding 5 fiscal
2 years.

3 (b) REPORT; STRATEGIC PLAN.—Not later than 180
4 days after the date of enactment of this Act, the Director
5 of the National Institutes of Health shall submit to the
6 Congress—

7 (1) a plan to perform the evaluation under sub-
8 section (a); and

9 (2) a plan to develop a strategy, based on such
10 evaluation, that will—

11 (A) be designed and implemented by the
12 Director in cooperation with a multidisciplinary
13 group of health professionals including gyne-
14 cologists, oncologists, endocrinologists, cardiolo-
15 gists, and neuroscientists;

16 (B) include strategies to resolve the gaps
17 in knowledge and research identified in the re-
18 port; and

19 (C) identify topics in need of further re-
20 search relating to potential treatments for
21 menopause-related symptoms.

22 **SEC. 3. ADDITIONAL RESEARCH RELATED TO MENOPAUSE,**
23 **PERIMENOPAUSE, OR MID-LIFE WOMEN’S**
24 **HEALTH.**

25 (a) ADDITIONAL RESEARCH.—

1 (1) IN GENERAL.—The Secretary of Health and
2 Human Services, acting through the Director of the
3 National Institutes of Health, shall conduct or sup-
4 port research related to menopause, perimenopause,
5 or mid-life women’s health.

6 (2) REQUIRED ELEMENTS.—The research re-
7 quired by paragraph (1) shall include—

8 (A) research concerning causes, symptoms,
9 and treatments for menopause, perimenopause,
10 and other related mid-life women’s health
11 issues; and

12 (B) a multidisciplinary study of the effects
13 of hormonal treatment for menopausal symp-
14 toms.

15 **SEC. 4. NO ADDITIONAL FUNDS AUTHORIZED TO BE APPRO-**
16 **PRIATED.**

17 No additional funds are authorized to be appro-
18 priated to carry out this section, and this section shall be
19 carried out using amounts otherwise available for such
20 purpose.

○